Related Experiment Video
Updated: Jun 3, 2026
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
Triple therapy in hospitalized patients: facts and controversies
John Fani Srour1, Gerald W Smetana
1Division of General Medicine and Primary Care, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA. jfanisro@bidmc.harvard.edu
Insights
Triple therapy, combining warfarin and dual antiplatelet therapy, increases bleeding risk but is crucial for patients with atrial fibrillation and coronary stents. This review aids clinicians in balancing risks and adhering to guidelines.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Triple therapy (warfarin plus dual antiplatelet therapy) use is rising due to aging populations and increased coronary stent procedures.
- This combination therapy significantly elevates bleeding risk compared to monotherapy.
- Warfarin alone risks stent thrombosis, while dual antiplatelet therapy inadequately prevents ischemic events in specific patient groups.
Purpose of the Study:
- To review current literature on antiplatelet and anticoagulant combinations.
- To guide optimal management of patients requiring triple therapy.
- To improve adherence to guidelines and reduce bleeding risk.
Main Methods:
- Literature review of antiplatelet and anticoagulant combinations.
- Analysis of risks and benefits in patients with atrial fibrillation and coronary stents.
- Synthesis of evidence to inform clinical practice.
Main Results:
- Triple therapy presents a complex risk-benefit profile.
- Balancing antithrombotic efficacy and bleeding is critical.
- Current guidelines aim to mitigate risks associated with combined therapies.
Conclusions:
- Optimal management requires careful consideration of individual patient factors.
- Adherence to evidence-based guidelines is essential for safe and effective treatment.
- Further research may refine strategies for managing triple therapy in complex patient populations.
Abstract:
The use of triple therapy (warfarin plus dual antiplatelet therapy) has increased in recent years due to an aging population with a higher risk for atrial fibrillation, as well as the increased use of coronary stents for acute coronary syndromes. Triple therapy confers a higher bleeding risk than either warfarin or dual antiplatelet therapy alone. However, warfarin alone is inadequate for patients with indications for triple therapy because of an unacceptable risk of stent thrombosis, and dual antiplatelet therapy is inferior to warfarin for the prevention of ischemic strokes in patients with atrial fibrillation, mechanical valves, or intraventricular thrombosis. Hospitalists face the challenge of balancing the aforementioned risks; the optimal management of these patients requires knowledge of the relevant literature and expertise. In this paper, we review the current literature on antiplatelet and anticoagulant combinations in patients with atrial fibrillation and coronary stents in order to improve adherence to published guidelines and to reduce the risk of bleeding.
Related Concept Videos
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
01:18Endocarditis III: Medical Management
01:29Venous Thrombosis III: Interprofessional Care
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
01:30Pneumonia III: Complications and Assessment